Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an expanded access designed to provide access to Repotrectinib for eligible participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Repotrectinib | Drug | Repotrectinib |
|
Inclusion Criteria:
-
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| BMS Study Connect Contact Center http://www.bmsstudyconnect.com | Contact | 855-907-3286 | Clinical.Trials@bms.com | |
| First line of the email MUST contain NCT # and Site #. | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| Pre-Approval Access (PAA) Healthcare Practitioner Requests | View source |
| FDA Safety Alerts and Recalls |
Not provided
| ID | Term |
|---|---|
| C000708510 | repotrectinib |
Not provided
Not provided
Not provided
| View source |